ArticleTranslational lung cancer research2025
Density and maturity ratio of tertiary lymphoid structures in stage II-III non-small cell lung cancer predict postoperative recurrence risk.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating the Toumai MT‑1000 for urologic surgery: a systematic review and single-arm meta-analysis with remote and on-site experiences.Journal of robotic surgery · 2025Pooled it
- Tertiary lymphoid structures predict the neoadjuvant chemoimmunotherapy response of stage III non-small cell lung cancer.Translational lung cancer research · 2026Article
- Advances in translational lung cancer research in 2025: a narrative review.Translational lung cancer research · 2026Review
- The biological characteristics of tertiary lymphoid structures in head and neck cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tertiary lymphoid structure (TLS) has been proposed to assess the prognosis of patients with cancer. Due to the heterogeneity of the tumor microenvironment, TLS varies significantly in tumor tissues of different patients. This study aims to explore TLS in tumor tissues from patients with stage II-III non-small cell lung cancer (NSCLC) and their impact on postoperative recurrence risk. Methods: A total of 118 patients who underwent curative surgery for pathologically confirmed primary stage II-III NSCLC were included in this study. The density of TLS in tumor tissue was assessed using hematoxylin and eosin (HE) stained sections. Multiplex immunofluorescence was employed to evaluate the maturity of TLS by labeling follicular dendritic cells (FDC) and germinal centers (GC). Grouping was based on density to maturity ratios and overall survival (OS) and recurrence-free survival (RFS) differences were compared between subgroups. Results: Both TLS density score (D score) and maturity score (M score) were significantly associated with 3- and 5-year prognosis and were identified as independent predictors of postoperative 5-year recurrence risk [D score: hazard ratio (HR) 0.344, 95% confidence interval (CI): 0.157-0.756; M score: HR 0.148, 95% CI: 0.031-0.695]. An immune scoring system that combines D and M scores categorized stage II-III NSCLC patients into three immune classes with distinct prognoses (P=0.02). Higher immune scores correlated with lower postoperative recurrence risk. Conclusions: The density and maturity ratio of TLS are significantly associated with RFS in patients with stage II-III NSCLC, and the density score correlates significantly with OS. A novel immune classification system is proposed for predicting postoperative recurrence risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.